American Gene Technologies CEO Jeff Galvin says the company's clinical trial has resulted in more patients with substantial increases in virus-specific T-cells with immunity against HIV.
Send this to friend
*By downloading the Insight, The Art of Tweeting you are also joining our newsletter.